• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Potential drug for Alzheimer’s disease prevention found safe and effective in animals

Bioengineer by Bioengineer
March 2, 2021
in Chemistry
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: ©2021 Rynearson et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20202560

Researchers at the University of California San Diego School of Medicine and Massachusetts General Hospital have identified a new drug that could prevent Alzheimer’s disease by modulating, rather than inhibiting, a key enzyme involved in forming amyloid plaques in the brain. The study, which will be published March 2 in the Journal of Experimental Medicine (JEM), demonstrates that the drug is safe and effective in rodents and monkeys, paving the way for future clinical trials in humans.

A key pathological hallmark of Alzheimer’s disease involves the formation of amyloid plaques composed of small protein fragments known as amyloid-β (Aβ) peptides. These peptides are generated by enzymes called β-secretase and γ-secretase, which sequentially cleave a protein called amyloid precursor protein on the surface of neurons to release Aβ fragments of varying lengths. Some of these fragments, such as Aβ42, are particularly prone to forming amyloid plaques, and their production is elevated in patients with mutations predisposing them to early-onset Alzheimer’s disease.

Several attempts have been made to treat or prevent Alzheimer’s disease using drugs that inhibit either β-secretase or γ-secretase. But many of these drugs have proved to be unsafe in humans, likely because β-secretase and γ-secretase are required to cleave additional proteins in the brain and other organs. A better approach could involve drugs known as γ-secretase modulators (GSMs), which, instead of inhibiting the γ-secretase enzyme, slightly alter its activity so that it produces fewer Aβ peptides that are prone to form plaques while continuing to cleave its other protein targets.

“GSMs therefore offer the ability to mitigate mechanism-based toxicities associated with γ-secretase inhibitors,” says Steven L. Wagner, PhD, a professor in the Department of Neurosciences at UC San Diego School of Medicine.

In the new study, Wagner and colleagues developed a novel GSM and tested it on mice, rats, and macaques. Repeated low doses of the drug completely eliminated Aβ42 production in mice and rats without causing any toxic side effects. The drug was also safe and effective in macaques, reducing Aβ42 levels by up to 70%.

The researchers then tested the drug in a mouse model of early-onset Alzheimer’s disease, treating the animals either before or shortly after they began to form amyloid plaques. In both cases, the novel GSM decreased plaque formation and reduced plaque-associated inflammation, which is thought to contribute to the development of disease.

This suggests that the drug could be used prophylactically to prevent Alzheimer’s disease, either in patients with genetic mutations that increase susceptibility to the disease or in cases where amyloid plaques have been detected by brain scans.

“In this study, we have pharmacologically characterized a potent GSM that, based on its preclinical attributes, appears to equal or exceed the potency of any previously tested GSMs,” adds Dr. Rudolph E. Tanzi, Professor of Neurology at Harvard and Massachusetts General Hospital. “Future clinical trials will determine whether this promising GSM is safe in humans and could be used to effectively treat or prevent Alzheimer’s disease.”

###

Rynearson et al., 2021. J. Exp. Med. https://rupress.org/jem/article-lookup/doi/10.1084/jem.20202560?PR

About Journal of Experimental Medicine

Journal of Experimental Medicine (JEM) publishes peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. All editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board. Established in 1896, JEM is published by Rockefeller University Press, a department of The Rockefeller University in New York. For more information, visit jem.org.

Visit our Newsroom, and sign up for a weekly preview of articles to be published. Embargoed media alerts are for journalists only.

Follow JEM on Twitter at @JExpMed and @RockUPress.

Media Contact
Ben Short
[email protected]

Original Source

https://rupress.org/jem/article-lookup/doi/10.1084/jem.20202560?PR

Related Journal Article

http://dx.doi.org/10.1084/jem.20202560

Tags: AlzheimerBiochemistryCell BiologyMedicine/Healthneurobiology
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

First-ever observation of the transverse Thomson effect unveiled

August 23, 2025
blank

Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

August 23, 2025

New Molecular-Merged Hypergraph Neural Network Enhances Explainable Predictions of Solvation Gibbs Free Energy

August 22, 2025

Shaping the Future of Dysphagia Diets Through 3D Printing Innovations

August 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Weather’s Impact on Anopheles Mosquito Populations in Lagos

Ghost Spider’s Maternal Care vs. New Fly Species

DWI-Guided vs. MRI-Based IMRT in Head & Neck

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.